LIT™ in Prostate Cancer

Detecting cancer's spread, for a brighter future ahead.

Seroxo's innovative approach to combining the LIT™ test with PSA-surveillance offers an unparalleled opportunity to improve early detection and subsequent clinical management.

Significant potential

Seroxo's proprietary LIT™ assay has been proven to be both sensitive and specific in detecting prostate cancer.

It is set to revolutionize patient management in the global prostate-cancer diagnostics market, which is projected to reach $4.16B by 2022 and grow at a CAGR of 14.6% through 2028*.

*Data from Market Business Insider Nov 2020

Seroxo's focus on developing the LIT™ technology and its clinical applications promises to save lives and reduce healthcare costs, making it a truly game-changing approach to prostate-cancer diagnostics